Nuwellis, Inc. announced that Henry Ford Health has begun offering ultrafiltration therapy to heart failure patients suffering from fluid overload using the company's Aquadex SmartFlow system as part of Nuwellis' pivotal REVERSE-HF clinical study.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2567 USD | -0.89% | +3.42% | -55.81% |
May. 07 | Top Midday Gainers | MT |
May. 07 | Nuwellis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.81% | 4.63M | |
+11.91% | 227B | |
+15.46% | 198B | |
+18.58% | 142B | |
+30.36% | 111B | |
+0.23% | 64.16B | |
+17.74% | 54.1B | |
+5.82% | 51.41B | |
+11.23% | 45.32B | |
+5.73% | 37.32B |
- Stock Market
- Equities
- NUWE Stock
- News Nuwellis, Inc.
- Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health